相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- AdvanCell closed an oversubscribed financing round totaling approximately $450 million (USD $315 million Series D), marking the largest-ever radiopharmaceutical capital raise in Australia. - Proceeds will fund Phase III registrational trials of ADVC001, a Lead-212 PSMA-targeted alpha radioligand therapy for metastatic prostate cancer, and expand US manufacturing infrastructure. - Phase Ib data for ADVC001 demonstrated encouraging anti-tumour activity and a favourable tolerability profile; Phase II expansion is evaluating 160 MBq and 200 MBq doses across three prostate cancer populations. - The financing underscores growing investor conviction in targeted alpha therapy, with major backers including Bain Capital Life Sciences, Fidelity, Eli Lilly, and Sanofi Ventures participating.
- AdvanCell has established its U.S. Global Headquarters in Greater Boston with a 128,000-square-foot flagship manufacturing facility to support development and commercialization of its Lead-212 targeted alpha therapies. - The company appointed Justyna Kelly as Chief Technology Officer and François Gaudet as Chief Scientific Officer, bringing extensive radiopharmaceutical manufacturing and oncology drug discovery expertise. - ADVC001, a PSMA-targeting radioligand labeled with Lead-212, is currently in a Phase 1/2 TheraPb trial (NCT05720130) evaluating safety and efficacy in metastatic prostate cancer. - The U.S. expansion and leadership appointments position AdvanCell to scale manufacturing for Phase 3 and commercial readiness while advancing its broader pipeline of targeted alpha therapies.
- Sydney-based AdvanCell secured a $315.0M Series D round to advance its targeted alpha radiopharmaceutical therapies for cancer and support their development and manufacturing. - The financing brings AdvanCell's total equity funding to $439.5M, with backing from Eli Lilly, Sanofi Ventures, Bain Capital Life Sciences, and other life science investors. - The round attracted a broad syndicate including Abingworth, Ally Bridge Group, Fidelity, T. Rowe Price, and Catalio Capital Management, underscoring investor conviction in radiopharmaceutical oncology. - Founded by Andrew Adamovich in 2019, AdvanCell operates across biotechnology, clinical trials, oncology, and pharmaceutical sectors.
- AdvanCell has appointed Andrew Kay, former CEO of Algeta ASA, as Chair-elect of its Board of Directors, bringing expertise from the successful $2.9 billion development and commercialization of Xofigo, the first approved alpha therapy. - Kay's appointment comes as AdvanCell advances its lead asset ADVC001, a potentially first-in-class PSMA-targeted alpha therapy, following promising Phase 1 trial results presented at ESMO. - The leadership transition positions AdvanCell to accelerate clinical development of its Lead-212 platform and expand manufacturing capabilities in the US for global late-stage development.
- AdvanCell will present the first clinical data for a Lead-212-based PSMA radioligand therapy at ESMO 2025, marking an important milestone in targeted alpha therapy development. - The Phase 1b dose escalation results from the TheraPb trial demonstrate a favorable safety profile and promising anti-tumor activity for ADVC001 in metastatic castration-resistant prostate cancer. - The presentation will feature updated safety and efficacy data from all seven Phase 1b treatment cohorts, with data cut-off as of May 9, 2025. - ADVC001 utilizes Lead-212, an alpha-emitting radionuclide with a 10.6-hour half-life, designed to deliver targeted radiation while minimizing toxicity.
- Swiss-based Debiopharm and French CRO Oncodesign Services have established a license agreement for AbYlink™, a regio-selective bioconjugation technology designed for therapeutic and non-invasive diagnostic applications. - The collaboration will utilize AbYlink™ to prepare antibody chelator conjugates for preclinical studies in molecular radiotherapy, with initial focus on radioimmunotherapy targeting HER2+ tumors in cancer models. - The partnership aims to provide broader access to non-invasive imaging applications and innovative solutions for biotech and pharmaceutical companies developing antibody and ADC-based therapeutics.
- Eli Lilly has secured rights to Sangamo Therapeutics' STAC-BBB capsid technology for $18 million upfront, with potential milestone payments reaching $1.4 billion plus tiered royalties. - The agreement allows Lilly to utilize Sangamo's proprietary adeno-associated virus capsid that can cross the blood-brain barrier to deliver genomic medicines targeting central nervous system diseases. - This partnership provides critical financial support for Sangamo, which had only enough cash to operate into Q1 2025 following Pfizer's termination of their hemophilia gene therapy collaboration.
• AdvanCell, a clinical-stage radiopharmaceutical company, has successfully raised $112 million in an oversubscribed Series C financing round co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis. • The company is currently conducting a Phase I/II dose escalation trial of ADVC001, a Pb-212-based Targeted Alpha Therapy for metastatic prostate cancer, with patients being enrolled in the highest dose cohort. • Since its founding in 2019, AdvanCell has grown to 60 team members with a 40,000-square-foot manufacturing facility and will use the new funding to expand manufacturing capacity and accelerate clinical development of its radiopharmaceutical pipeline.
